Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of intravenous opioid agonist therapy with Hydagelan in Vienna
2024-519652-90-01Phase 2Completed
- Sponsor
- Suchthilfe Wien
- Start
- Feb 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hydromorphone in opioid use disorder (OUD), sponsored by Suchthilfe Wien. Primary endpoints: Reduction of intravenous opioid use outside the medical setting and Feasibility of implementation and execution. Started Feb 2025; status: completed.
02
Drugs
hydromorphone
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on 2024-519652-90-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519652-90-01.